The importance of facts in science: the Black Swan Research Initiative search for the cure moves ahead

The IMF’s Black Swan Research Initiative® took a major step forward this week in its mission to achieve a cure for myeloma. A study published in the journal Leukemia definitively establishes Next Generation Flow (NGF) as a highly sensitive, fully standardized approach for Minimal Residual Disease (MRD) detection in myeloma. This method, the study’s authors write, “overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.”

Real Food for 2017

As many of you know, I have written close to 20 blog posts about food (available here), a favorite topic.  The subject has been in the news so often lately that it seems like a good time to update my comments.

The good and the good for 2017: how results of the SWOG 0777 trial and serum Freelite testing can help myeloma patients

I often discuss the good and the bad in the news. But I thought it would be great to start 2017 with just the good! The SWOG 0777 trial results, recently published in The Lancet, and serum Freelite testing, just published in Blood, will help day-to-day care of myeloma patients in a variety of ways. Both studies are considered important and have accompanying commentaries or editorials in the journals reflecting that. In a year-end review to be published shortly in Nature Reviews Clinical Oncology, the SWOG 0777 study is identified as the major “practice changing” trial for 2016.

ASH 2016: A negative study is great news for patients

Among the 688 myeloma-related abstracts presented at the Annual Meeting of the American Society of Hematology (ASH) this year, one stands out. This is “Late-Breaking Abstract: LBA-1,” presented by Dr. Ed Stadtmauer on Tuesday, December 6th at 7:30 am.

Successful iStopMM launch pioneers a new way to manage disease

This week, the iStopMM team launched the ambitious screening, treatment, and prevention program for MGUS, SMM, and MM in Iceland.